StockMacro
Company, fund or insider

Help

Menu

Ryan Savitz

Insider (Form 4 reporting owner): EVP, CFO & CBO CIK 1992324Name as filed: Savitz RyanIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 9 Sep 2025, sold $26.2M in 6 sales (6 under a 10b5-1 plan set in advance) of Dianthus Therapeutics.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Dianthus Therapeutics DNTHEVP, CFO & CBO9 Sep 20259 Nov 2026–6$26.2M

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After salestoo few trades4 tradestoo few trades3 tradestoo few trades1 trade

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
2026––4$24.6M-$24.6M
2025––2$1.6M-$1.6M

Every trade

6, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
9 Nov 2026Dianthus Therapeutics DNTHSellafter exercising options124,042$90.52$11.2M10b5-1 planForm 4filed 12 Nov 2026
9 Jul 2026Dianthus Therapeutics DNTHSellafter exercising options31,249$101.03$3.2M10b5-1 planForm 4filed 13 Jul 2026
9 Apr 2026Dianthus Therapeutics DNTHSellafter exercising options8,224$89.84$739K10b5-1 planForm 4filed 10 Apr 2026
31 Mar 2026Dianthus Therapeutics DNTHSellafter exercising options114,367$83.00$9.5M10b5-1 planForm 4filed 1 Apr 2026
4 Dec 2025Dianthus Therapeutics DNTHSellafter exercising options20,000$45.18$904K10b5-1 planForm 4filed 5 Dec 2025
9 Sep 2025Dianthus Therapeutics DNTHSellafter exercising options20,000$35.00$700K10b5-1 planForm 4filed 11 Sep 2025

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.